About Preventable Vaccines
Vaccines can be defined as a product that stimulates a person’s immune system to produce immunity to a specific disease, thereby protecting the person from that disease. According to the CDC, vaccines are usually administered through needle injections, but can also be administered orally or sprayed into the nose. Vaccines can be used for both adults and infants and adolescents. Pediatric vaccines are used for the immunization of children to give protection against various infectious diseases such as diphtheria, influenza, hepatitis, pneumococcal diseases, and meningococcal diseases. According to the classification adopted by the US FDA, children are classified as newborn, infant, and adolescent, ranging from birth to 21 years of age. However, the EMA classifies pediatrics as ranging from birth to 18 years of age.
TechNavio's analysts forecast the Global Preventable Vaccines market to grow at a CAGR of 10.16 percent over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Preventable Vaccines market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of preventable vaccines. The report examines the market for vaccines used in humans. It covers only commercialized vaccines for diseases that are vaccine preventable.
The report does not cover emerging vaccines for diseases that are not currently vaccine preventable, such as Ebola infection, Epstein-Ban virus infection, Alzheimer's disease, diabetes, Helicobacter pylori infection, multiple sclerosis, Parkinson's disease, or West Nile virus infection.
The report has broadly categorized preventable vaccines into two major segments:
• Adult Preventable Vaccines
• Pediatric Preventable Vaccines
TechNavio's report, the Global Preventable Vaccines Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Preventable Vaccines market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• GlaxoSmithKline
• Merck
• Novartis
• Pfizer
• Sanofi
Other Prominent Vendors
• Abbott
• AstraZeneca
• Bavarian Nordic
• Baxter
• Bharat Biotech
• Bharat Immunologicals and Biologicals
• bioCSL
• Bio Med
• Crucell
• Dynavax Technologies
• Indian Immunologicals
• Janssen Pharmaceuticals
• Kaketsuken
• LG Life Sciences
• Mitsubishi Tanabe Pharma
• Lupin
• Nuron
• Protein Sciences
• Panacea Biotec
• Roche
• Serum Institute of India
• Shenzhen Kangtai Biological Products
• Serum Institute of India
• Sinovac Biotech
• S K Chemicals
• Takeda Pharmaceutical
• Valeant Pharmaceuticals
• Zydus Cadila
Market Driver
• Inclusion in NIP
• For a full, detailed list, view our report
Market Challenge
• Inadequate Vaccine Coverage
• For a full, detailed list, view our report
Market Trend
• Increase in Strategic Alliances
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Vaccine Approval Process
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Global Adult and Pediatric Preventable Vaccine Market Share 2014-2019
07.4 Five Forces Analysis
08. Market Segmentation by Type of Vaccine
08.1 Live Attenuated Vaccine
08.2 Killed Vaccine
08.3 Toxoid Vaccine
08.4 Genetically Modified/Engineered Vaccine
09. Market Segmentation by Product Type
09.1 Polysaccharide Vaccines
09.2 Conjugate Vaccines
10. Geographical Segmentation
11. Global Preventable Vaccines Market by Key Geographies
11.1 Market Size and Forecast for the US
11.2 Market Size and Forecast for the EU
11.3 Market Size and Forecast for Japan
11.4 Market Size and Forecast for India
11.5 Market Size and Forecast for China
12. Global Pediatric Preventable Vaccines Market
12.1 Global Pediatric Preventable Vaccine Market
12.1.1 Market Size and Forecast
12.2 Market Segmentation of the Global Pediatric Preventable Vaccine Market
12.3 Global Pediatric Hepatitis Vaccines Market
12.3.1 Market Size and Forecast
12.4 Global Pediatric Haemophilus Influenzae Type B (Hib) Vaccines Market
12.4.1 Market Size and Forecast
12.5 Global Pediatric MMR Vaccines Market
Market Size and Forecast
12.6 Global Pediatric Combination Vaccines Market
12.6.1 Market Size and Forecast
12.7 Global Pediatric Pneumococcal Vaccines Market
12.7.1 Market Size and Forecast
12.8 Global Polio Vaccines Market
12.8.1 Market Size and Forecast
12.9 Global Pediatric Varicella Vaccines Market
12.9.1 Market Size and Forecast
12.10 Global Other Pediatric Vaccines Market
12.10.1 Market Size and Forecast
12.11 Global Pediatric Preventable Vaccines Market 2014 and 2019 (by percentage)
13. Global Adult Preventable Vaccines Market
13.1 Market Size and Forecast
13.2 Market Segmentation of the Global Adult Preventable Vaccines Market
13.3 Global Adult Cervical Vaccines Market
13.3.1 Market Size and Forecast
13.4 Global Adult Hepatitis Vaccines Market
13.4.1 Market Size and Forecast
13.5 Global Adult Influenza Vaccines Market
13.5.1 Market Size and Forecast
13.6 Global Adult Pneumococcal Vaccines Market
13.6.1 Market Size and Forecast
13.7 Global Adult Travel, Diphtheria-Tetanus, and Miscellaneous Vaccines Market
13.7.1 Market Size and Forecast
14. Key Leading Countries
14.1 US
14.2 China
14.3 Japan
14.4 India
15. Buying Criteria
16. Market Growth Drivers
17. Drivers and their Impact
18. Market Challenges
19. Impact of Drivers and Challenges
20. Market Trends
21. Trends and their Impact
22. Vendor Landscape
22.1 Competitive Scenario
22.1.1 Key News
22.1.2 Mergers and Acquisitions
22.2 Market Share Analysis 2014
22.2.1 GlaxoSmithKline
22.2.2 Merck
22.2.3 Novartis
22.2.4 Pfizer
22.2.5 Sanofi
22.3 Other Prominent Vendors
23. Key Vendor Analysis
23.1 GlaxoSmithKline
23.1.1 Key Facts
23.1.2 Business Overview
23.1.3 Business Segmentation
23.1.4 Business Segmentation by Revenue 2012 and 2013
23.1.5 Sales by Geography
23.1.6 Pipeline Products
23.1.7 Business Strategy
23.1.8 Key Information
23.1.9 SWOT Analysis
23.2 Merck
23.2.1 Key Facts
23.2.2 Business Overview
23.2.3 Business Segmentation by Revenue 2013
23.2.4 Business Segmentation by Revenue 2012 and 2013
23.2.5 Sales by Geography
23.2.6 Business Strategy
23.2.7 Key Developments
23.2.8 SWOT Analysis
23.3 Novartis
23.3.1 Key Facts
23.3.2 Business Description
23.3.3 Business Segmentation
23.3.4 Revenue by Business Segmentation
23.3.5 Revenue Comparison 2012 and 2013
23.3.6 Sales by Geography
23.3.7 Business Strategy
23.3.8 Key Developments
23.3.9 SWOT Analysis
23.4 Pfizer
23.4.1 Key Facts
23.4.2 Business Overview
23.4.3 Business Segmentation by Revenue 2013
23.4.4 Business Segmentation by Revenue 2012 and 2013
23.4.5 Geographical Segmentation by Revenue
23.4.6 Business Strategy
23.4.7 Key Developments
23.4.8 SWOT Analysis
23.5 Sanofi
23.5.1 Key Facts
23.5.2 Business Description
23.5.3 Business Segmentation
23.5.4 Revenue by Business Segmentation
23.5.5 Revenue Comparison 2012 and 2013
23.5.6 Sales by Geography
23.5.7 Business Strategy
23.5.8 Key Developments
23.5.9 SWOT Analysis
24. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Vaccine Approval Process
Exhibit 3: Global Preventable Vaccines Market 2014-2019 (US$ million)
Exhibit 4: Global Preventable Vaccines Market Categories
Exhibit 5: Global Adult and Pediatric Preventable Vaccine Market Share 2014-2019 (US$ million)
Exhibit 6: Global Preventable Vaccines Market Share by Vaccine Type 2014 and 2019
Exhibit 7: Global Preventable Vaccines Market Segmentation by Type of Vaccine
Exhibit 8: Global Preventable Vaccines Market Segmentation by Product Type
Exhibit 9: Global Preventable Vaccines Market by Geographical Segmentation 2014
Exhibit 10: Global Preventable Vaccines Market by Region 2014-2019 (US$ million)
Exhibit 11: Global Preventable Vaccines Market in the US 2014-2019 (US$ million)
Exhibit 12: Global Preventable Vaccines Market in the EU 2014-2019 (US$ million)
Exhibit 13: Global Preventable Vaccines Market in Japan 2014-2019 (US$ million)
Exhibit 14: Global Preventable Vaccines Market in India 2014-2019 (US$ million)
Exhibit 15: Global Preventable Vaccines Market in China 2014-2019 (US$ million)
Exhibit 16: Global Pediatric Preventable Vaccines Market 2014-2019 (US$ million)
Exhibit 17: Global Pediatric Preventable Vaccines Market Segmentation
Exhibit 18: Global Pediatric Hepatitis Vaccines Market 2014-2019 (US$ million)
Exhibit 19: Global Pediatric Haemophilus Influenzae Type B Vaccines Market 2014-2019 (US$ million)
Exhibit 20: Global Pediatric MMR Vaccine Market 2014-2019 (US$ million)
Exhibit 21: Global Pediatric Combination Vaccines Market 2014-2019 (US$ million)
Exhibit 22: Global Pediatric Pneumococcal Vaccines Market 2014-2019 (US$ million)
Exhibit 23: Global Polio Vaccines Market 2014-2019 (US$ million)
Exhibit 24: Global Pediatric Varicella Vaccines Market 2014-2019 (US$ million)
Exhibit 25: Global Other Pediatric Vaccines Market 2014-2019 (US$ million)
Exhibit 26: Global Pediatric Preventable Vaccines Market by Vaccine Segmentation (2014 and 2019) (US$ Million)
Exhibit 27: Global Pediatric Preventable Vaccines Market by Vaccine Segmentation 2014 (in %)
Exhibit 28: Global Pediatric Preventable Vaccines Market by Vaccine Segmentation 2019 (in %)
Exhibit 29: Snapshot of Global Pediatric Preventable Vaccines Market by Segments 2014-2019
Exhibit 30: Global Adult Preventable Vaccines Market 2014-2019 (US$ million)
Exhibit 31: Global Adult Cervical Vaccines Market 2014-2019 (US$ million)
Exhibit 32: Global Adult Hepatitis Vaccines Market 2014-2019 (US$ million)
Exhibit 33: Global Adult Influenza Vaccine Market 2014-2019 (US$ million)
Exhibit 34: Global Adult Pneumococcal Vaccines Market 2014-2019 (US$ million)
Exhibit 35: Global Travel, Diphtheria-Tetanus, and Miscellaneous Vaccines Market 2014-2019 (US$ million)
Exhibit 36: Global Adult Preventable Vaccines Market by Vaccine Segmentation (2014 and 2019) (US$ Million)
Exhibit 37: Global Adult Preventable Vaccines Market by Vaccine Segmentation 2014 (in %)
Exhibit 38: Global Adult Preventable Vaccines Market by Vaccine Segmentation 2019 (in %)
Exhibit 39: Snapshot of Global Adult Preventable Vaccines Market by Segments 2014-2019
Exhibit 40: Buying Criteria of the Global Preventable Vaccines Market
Exhibit 41: Drivers and their Impact on the Key Customer Category of the Global Preventable Vaccines Market
Exhibit 42: Drivers and their Impact on Geographies in Global Preventable Vaccines Market
Exhibit 43: GlaxoSmithKline's Revenue 2013
Exhibit 44: GlaxoSmithKline: Vaccine Pipeline
Exhibit 45: Merck's Revenue 2013
Exhibit 46: Novartis' Revenue 2013
Exhibit 47: Novartis: Vaccine Pipeline
Exhibit 48: Pfizer's Revenue 2013
Exhibit 49: Sanofi's Revenue 2013
Exhibit 50: GlaxoSmithKline: Business Segmentation 2013
Exhibit 51: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 52: GlaxoSmithKline: Sales by Geography 2013
Exhibit 53: GlaxoSmithKline: Pipeline Products 2013
Exhibit 54: Merck & Co. Inc.: Business Segmentation by Revenue 2013
Exhibit 55: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 56: Merck & Co. Inc.: Sales by Geography 2013
Exhibit 57: Novartis AG: Business Segmentation
Exhibit 58: Novartis AG: Revenue by Business Segmentation 2013
Exhibit 59: Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 60: Novartis AG: Revenue by Geographical Segmentation 2013
Exhibit 61: Pfizer: Business Segmentation by Revenue 2013
Exhibit 62: Pfizer: Business Segmentation by Revenue 2012 and 2013
Exhibit 63: Pfizer: Geographical Segmentation by Revenue 2013
Exhibit 64: Sanofi SA: Business Segmentation
Exhibit 65: Sanofi SA: Revenue by Business Segmentation 2013
Exhibit 66: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 67: Sanofi SA: Sales Revenue by Geographical Segmentation 2013
Contact us at the Consulting WP office nearest to you or submit a business inquiry online.
Subscribe to Our Newsletter
Published On : December 2019
$ 3600
Published On : November 2019
$ 3600
Published On : October 2019
$ 2950
Published On : October 2019
$ 2950
Published On : October 2019
$ 2950